^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS R68M

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    KRAS mutant gene editing prevents tumor growth in vivo and overcomes acquired resistance to KRASG12C inhibitor. (EACR 2023)
    We demonstrated a synergistic combination between ADGN-121/Abraxane in pancreatic carcinoma and between ADGN-122/Capecitabine in colon Adenocarcinoma. We showed, that ADGN-123 containing gRNAG12C can effectively reduce the proliferation and inhibit ERK phosphorylation of sotorasib/adagrasib acquired resistance cells harboring KRASG12C/R68M and KRASG12C/Y96D mutations...ConclusionOur study provides a proof-of-concept that ADGN can be applied to target driver mutations of cancers in vivo and permanently disrupt the oncogenic alleles, leading to major tumor regression. ADGN-123 constitutes an alternative strategy to overcome resistance associated to inhibitors of KRASG12C.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS Y96D • KRAS R68M • KRAS V12
    |
    capecitabine • Lumakras (sotorasib) • albumin-bound paclitaxel • Krazati (adagrasib)